BPPI RC For Surgical Items

NOT TRANFERABLE
TENDER NO. :- BPPI/Drugs&SurgicalTesting/048-2017
TENDER FOR EMPANELMENT OF DRUGS TESTING

LABORATORIES FOR ANALYSIS OF DRUGS
MEDICINES & SURGICAL FOR 2017-2019
Dated: 02.03.2017
BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Govt. of India)
IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON 122016
Telephone: 0124-4303751/56; Fax: 0124-2340370 Website: janaushadhi.gov.in
BPPI/Drug & Surgical Testing/048

Page 1
BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)
(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)
Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003 Working
Office: IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON (HR)
TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR

ANALYSIS OF DRUGS & MEDICINES FOR 2016-2018
Important Dates:
Tender Reference Number BPPI/Drug & surgical Testing/048-2017
Date 09/03/2017
Date of availability of Tender 09/02/2017 (Thursday)
documents on website
Last date and time for receipt of 02/03/2017 (Thursday )15.00 hrs
Tender
Date and time of Opening of 02/03/2017 (Thursday)15.30 hrs
Tender
Place of Opening of Tender BPPI, IDPL Corporate Office, IDPL
Complex, Dundahera, Gurgaon (HR)
Address For Communication BPPI, IDPL Corporate Office, IDPL
Complex, Dundahera, Gurgaon (HR)-
122016
Contact Person for clarification if any:
1. Ms. Reena Bhagat 2. Mr. Mahadev Agarwal,
Dy. Mgr(Quality and Regulatory) Manager (Procurement)
Phone: 0124-4040768 Phone: 0124-45567554

Mob: 8130704311 Mob: 9873294473
Email:reg2.bppi@gmail.com Email: mahadevpharm.bppi@gmail.com

Page 2
CONTENTS
Sl. No. Description Page No.

1 Last date for receipt of tender 04
2 Eligibility criteria 04
3 Technical bid – Cover -‘A’ including Earnest Money Deposit & other 05
Documents
4 Price bid – Cover -‘B’ 06
5 General conditions 07
6 Acceptance of tender(Opening of Cover -‘A’ and Cover-‘B’ of tender) 07
7 Agreement 08
8 Security Deposit 08
9 Complete Analysis and Reporting Condition 08
10 Payment Provisions 10
11 Penalties Provisions 10
12 Black Listing Procedure 10
13 Agreement Format 11-14
14 Annexure-I : Performa for Performance Statement 16
15 Annexure –II : Details of Laboratory and Certificate of Registration for 17
Service Tax
16 Annexure-III (A) Personnel in Laboratory 18
17 Annexure-III (B) List of Sophisticated Instruments 18
18 Annexure-III (C) Facilities in Microbiological Section 19
19 Annexure-IV: Declaration Form 20
Annexure VA : List of DRUGS
Annexure VB : List of Surgical
20 21-25
21 Annexure VI Declaration as per para 2(e) &5 vi 26
22 Annexure VII : Checklist 27
23 Annexure VIII : Cover -‘B’ (Price bid) in a separate cover 28

Page 3
BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA
(Set up under Department of Pharmaceuticals, Govt. of India)
TENDER FOR EMPANELMENT OF DRUGS & SURGICAL TESTING

LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR BPPI FOR
TWO YEAR (2017-19) FROM THE DATE OF ACCEPTANCE OF TENDER
“CONFIDENTIALITY IS THE ESSENCE OF THIS TENDER”
1. Sealed tenders are invited till 02/03/2017 Thursday(15.00 hours) by CEO BPPI at
Bureau of Pharma Public Sector Undertakings of India (BPPI), IDPL Corporate Office,
IDPL Complex, Dundahera, Gurgaon-122016 (Haryana), (Herein referred as Tender
inviting authority unless the context otherwise requires) for empanelment of approved
drug testing laboratories (under Drugs & Cosmetics Act 1940 & Rules 1945) which are GLP
compliant (as per Schedule L1) and NABL accredited for drugs requiring Chemical/Physico-
chemical, instrumental and microbiological testing facilities for a period of two years from
the date of acceptance of tender by BPPI. The agreement may be extended for further period
on mutually agreed terms.
The complete set of tender document can be downloaded from the BPPI website
janaushadhi.gov.in and CPP portal i.e eprocure.gov.in free of cost.
NOTE:- LATE TENDER IS NOT ACCEPTABLE
2. Eligibility Criteria:
(a). National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited
analytical laboratories having approval/license under the Drugs and Cosmetics Act and Rules 1945
with minimum two years experience in the analysis of DRUGS & MEDICINES with an minimum
average annual turnover of Rs. 30 Lakhs for last two years i.e 2014-15and 2015-16 (Govt./CPSU’s
Laboratories, Research and Development Laboratories, Laboratories run by Co-operative body and
Educational Institutions are exempted from the turnover criteria) however turnover for the year
2014-15 should not be less than Rs. 30 lakhs, are eligible to participate in the tender. Agents are
not eligible to participate in the tender.
(b). Drug Testing Laboratory which is also engaged in manufacturing of medicines and participate in
drug procurement as well as drug testing Laboratory tender shall not be considered for testing
laboratory empanelment as eligible if their product achieve L-1 rate in any drug procurement tender
by BPPI.
(C). Drug Testing laboratories should have Approval/ license under Drugs & Cosmetics Act and
Rules 1945 , with two years standing in the analysis of Drugs & Medicines.

Page 4
(d). Drug Testing laboratories should be GLP compliant under the provisions of Drugs & Cosmetics
Act 1940 and Rules 1945 and should hold Schedule L1 certificate.
(e). Drug Testing laboratories should not have been banned/debarred/ black listed/deregistered by
any State or Central Govt. Organizations or its procurement agencies on the due date of bid
submission.
(f). Drug Testing laboratory and its responsible persons should not have ever been convicted under
the D & C Act 1940 and Rules 1945.
(g). Drug Testing laboratory should have all necessary instruments/equipments and required
mandatory facilities for testing/analysis of Drugs and Medicines as per statutory requirement for
which it is participating in the tender.
(h) Attested copy of approval and GLP Certificate of Drug Testing laboratory, duly renewed up to
date issued by the state licensing authority be submitted.
3. Technical bid – Cover -‘A’ including Earnest Money Deposit & other Documents:
The tenderer must submit the following documents in the sealed cover super scribed Cover -‘A’ (all
the documents have to be sealed and copies have to be self attested and notarized in all pages).
[a]. The Earnest Money Deposit (EMD) shall be Rs.10,000/-(Rupees Ten Thousand only) paid in the
form of Demand Draft or Banker Cheque drawn in favour of BUREAU OF PHARMA
PUBLIC SECTOR UNDERTAKINGS OF INDIA payable at Delhi/Gurgaon, should be sent with
tender form in Cover- ‘A’. The EMD is refundable however it will not earn any interest. EMD in the
form of cheque/ cash/ postal order/ e-payment will not be accepted.
The EMD amount of unsuccessful bidder will be refunded to them within 30 days of finalization of
tender. In respect of successful bidder (empanelled bidder), the EMD amount will be adjusted
towards security deposit.
[b]. Self attested and notarized photocopies of Approval/ license issued by State Licensing
Authority duly renewed up to date and NABL accreditation certificate.
[c]. Documentary evidence of having analyzed DRUGS & Surgical for the last two years with
the statement in the performa given in Annexure-I
[d]. Self attested and notarized photocopy of certificate of registration for Service Tax should be
enclosed in Annexure-II.
[e]. Non conviction certificate issued by State Licensing Authority (SLA)/Competent Authority
which should not be 6 months old on date of submission of bid.

Page 5
[f]. Self attested and notarized document of the following should be furnished in the format given in
Annexure-III
(i). List of qualified personnel employed in Drug Testing laboratory along with their
qualification, experience and details of their approvals (copy of the approval).
(ii). List of sophisticated instruments (working condition) available in Drug Testing

laboratory.
(iii). Facilities available in Microbiological Section in the laboratory
[g]. A declaration in the Performa given in Annexure-IV duly signed and notarized.
[h]. Details of DRUGS & Surgical to be analyzed to be given in Annexure-VA & VB
[i]. Documentary evidence regarding constitution of Drug Testing laboratory viz. Memorandum
and Articles of Association, partnership deed etc, with details of name, address, telephone no., fax
no., e-mail address of Managing Director/ Partner/ Proprietor etc.
[j]. The instruments such as power of attorney, Resolution of Board etc authorizing the tenderer,
should be enclosed in the tender (in Cover-‘A’) duly signed by authorized signatory of the Drug
Testing laboratory. Such authorized signatory of the tenderer should sign at the bottom of all the
pages of the tender documents.
OTHER DOCUMENTS TO BE ENCLOSED: [self attested and notarized]
(k). Annual turnover statement certified by the auditors (C.A.) for last two years i.e., 2014-15 and
2015-16.
(l). Tenderer shall submit the checklist of documents in the enclosed performa in Annexure –VII
4. PRICE BID (COVER-‘B’)
(a). Price Bid (Annexure VIII) of the tenderer duly filled in giving the rate of testing, charges for
complete testing of each sample and signed on each page by authorized person with company seal,
should be sent in separate sealed cover indicating name of the tenderer and superscribing “Price Bid”
Cover –‘B’ hereafter called Cover-‘B’.
(b). Cover-‘B’ shall contain the rates quoted by the tenderer only. It shall not contain any other
document. No condition shall be indicated in the price bid. All the terms and conditions shall be
indicated only in the technical bid.
(c). The tender documents and certificates must be submitted in a separate sealed cover as Cover-‘A’
and Price Bid shall be kept in separate sealed cover as Cover-‘B’. Both Cover-‘A’ and Cover-‘B’
shall be kept in single sealed cover on which it shall be superscribed as “TENDER FOR

Page 6
EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS &
Surgical FOR TWO YEARS (2017-2019)
(d). The tender document should reach Manager (A&F), BPPI, IDPL Corporate Office, IDPL
Complex, Dundahera, Gurgaon-122016 (Haryana), till 02.03.2017 by 15.00 hour.
(e). If the last date of submission is declared holiday, the tenders may be submitted on next working
day upto 10.30 A.M.
(f). Tenderers should also enclose soft copy of Price Bid in CD along with Cover-
‘B’
5. GENERAL CONDITIONS
i. Forms in all annexure should be filled up properly. Every correction should invariably be
attested by tenderer, failing which the tender will be summarily rejected.
ii. The tenderer should quote the rates for complete analysis as per the pharmacopoeial or other
standards as per provisions of Drugs and Cosmetics Act 1940 for each drug and medicine not for
individual test to be performed.
iii. The rates should be exclusive of taxes.
iv. The rates quoted and accepted will be binding on the tenderer for stipulated period and on no
account any revision will be entertained till the completion of the contract period.
v. If in any circumstances (like breakdown of instrument or non-availability of reference

standard and impurities etc.) the Drug Testing Laboratory is unable to test sample of Medicines, the
same should be reported within 24 hours from time of breakdown of instrument or non-availability of
reference standard of such sample by fax/ e-mail to Dy. Manager Quality & Regulatory.
vi. The tender submitted by the laboratory which has been banned/debarred
blacklisted/deregistered by the State / Central Govt. organization, shall not be considered.(Annexure
VI).
vii. The laboratory will not be permitted to outsource any test from other Drug Testing laboratory.
6. ACCEPTANCE OF TENDER
i. Out of two covers submitted by each tenderer, Cover- ‘A’ will be opened first at 15.30 hours
on 02/03/2017 in the presence of tenderers or their authorized representatives who chooses to be
present. After scrutiny of the documents and information furnished in Cover-‘A’ and confirmation of
details stated therein, a list of eligible laboratories will be shortlisted.
ii. Cover-‘B’ (Price Bid) of the tenderers found eligible on the basis of scrutiny of Cover-‘A’
will be opened subsequently and the date and time for opening of Cover-‘B’ will be intimated to the

Page 7
shortlisted tenderers. The acceptable rates for analysis will be decided on the basis of L1 rates and
will be communicated.
iii. The tenderers other than L1 tenderer will be given opportunity to match L1 rate and after due
confirmation, their name/s will be included in the panel. If required, the empanelled laboratories will
be inspected by team of officials of BPPI as and when need arises. In case sufficient Laboratories are
not empanelled due to any reason, BPPI reserves right to float fresh tender during period of two
years.
iv. The tender inviting authority, BPPI reserves the right to accept or reject any tender for any
one or more of the items tendered for, without assigning any reason.
v. No tenderer will be allowed to withdraw their bid after opening of Price Bid.
7. AGREEMENT
All tenderer who are empanelled will have to execute an agreement on non-judicial stamp paper of
Rs. 100/-(stamp duty to be paid by tenderer) in favour of BUREAU OF PHARMA PUBLIC
SECTOR UNDERTAKINGS OF INDIA within 15 days from the date of intimation received by
them from BPPI that their tenders have been accepted. The form of agreement is available under
para13 of tender document.
8. SECURITY DEPOSIT
The successful tenderers must pay a security deposit of Rs. 20,000/-(Rupees Twenty Thousand only)
including adjustment of EMD amount at the time of execution of agreement referred in Para 7 above
by way of DD or Banker Cheque in favour of BUREAU OF PHARMA PUBLIC SECTOR
UNDERTAKINGS OF INDIA payable at Delhi/Gurgaon.
9. COMPLETE ANALYSIS AND REPORTING CONDITION
(a). On empanelment and entrustment of the job, the Drug Testing Laboratory should furnish the test
reports within,
(i). 8 days of receipt of sample in case of Tablet, Capsules, Ointment, Cream, Gel, Powder and
Liquid oral preparations (all non-sterile dosage forms).
(ii). 21 days of receipt of sample in case of LVP/SVP, Inject able in vial/Ampoules and Dry Powder
Injectable (all sterile dosage forms).
(iii). Within 24 hours of receipt of sample, the confirmation of receipt should be given to BPPI by fax
/ mail.

Page 8
(iv). For any delay more than stipulated time as mentioned in para 9 (a)(i) and (ii) as the case may be,
5% of testing charges per week and the part thereof would be deducted as penalty. For consecutively
delay for 4 times or more than 8 times in a year or a delay of more than 10 days occurs over the time
period stipulated above, then the penalty would be 10% of testing charges per week and part thereof.
(b). All the test mentioned under IP, BP, USP and any other standard mentioned as per Second
Schedule of under D& C Act 1940 and Rules 1945 as well as Schedule V should be carried out for
each and every sample. The results obtained in the test should be mentioned in figures. Test reports
not mentioning complete details as per IP, BP, and USP etc will be considered as “Incomplete test
report” and the drugs testing laboratory will have to submit complete report for acceptance.
(c). “Complies” or “Passes” or “Within Limit” in result column of the test report will also be treated
as incomplete test report, if the result has some value the actual value found on analysis is to be
reported.
(d). Every test report must have some specific remarks as ‘Standard Quality’, or ‘Not of Standard
Quality.’ Any ambiguity/ cutting will not be accepted.
(e). Test report should have Sr. No., Description of tests, Specifications and Results obtained
including protocol of test applied.
(f). Spectra/Chromatograph/Dissolution profile, or other data sheets, wherever applicable, should be

attached with the test report.
(g). In the case of non-pharmacopoeial products the method of analysis should be mentioned in the
report AND PROTOCOL OF TEST APPLIED TO BE MENTIONED ON EACH REPORT,
(h). The test report should be sent to Dy. Manager (Quality & Regulatory), BPPI office as hard copy
and simultaneously scanned copy should be sent by e-mail reg2.bppi@gmail.com.
(i). All test report should be submitted to BPPI in duplicate. In case of failure of sample, result should
be communicated immediately toDy. Manager (Quality & Regulatory), BPPI through phone/ fax/ e-
mail and physical report should be sent with covering letter addressed to Manager (Regulatory) at
Bureau of Pharma Public Sector Undertakings of India (BPPI), IDPL Corporate Office, IDPL
Complex, Dundahera, Gurgaon-122016 (Haryana).
(j). If in any circumstances (like breakdown of instrument or non-availability of reference standard

etc.) the Drug Testing Laboratory is unable to undertake sample, the same should be reported within
24 hours of receipt of such sample by fax/ e-mail to Dy Manager Regulatory and sample should be
returned to him immediately. 100% of charges as penalty will be imposed in case no prior
information of breakdown of instrument or non-availability of reference standard before sending
samples. Refer para (5)(v).
(k). If any sample is received in damaged condition by the laboratory, the sample should not be
analyzed and should be sent back immediately to Dy. Manager (Quality and Regulatory), BPPI and
due information should be given by fax/ e-mail.
Page 9
(l). Dy. Manager (Quality and Regulatory), BPPI or authorized representatives have the right to
inspect the laboratories of the tenderer who have submitted tenders before taking any decisions
regarding empanelment. He/She may also inspect any laboratory which is empanelled at any time
during continuance of tender and initiate action to terminate / cancel its empanelment and not to
entrust any further testing job to the laboratory if any violation of tender conditions are noticed
during such inspections.
10. PAYMENT PROVISIONS
i. No advance payment towards any analysis will be made to tenderer.
ii. No payment will be made for incomplete analysis or incomplete report. Refer Para 9 (b) to 9
(g)
iii.(a).Payments towards the analysis of DRUGS & MEDICINES & Surgical will be made along with
tax at the prevailing rate as applicable at the time of payment strictly as per rules
(b). Bills should be supported with the copy of test report. Efforts will be made to make payments
within 30 days from the date of receipt of the bills by BPPI if same are found in order in all respect.
11. PENALTIES PROVISIONS
If the successful tenderer fails to execute the agreement and payment of security deposit after opening of
Price Bid within the specified time or withdraws the tender after the intimation of acceptance of tender
has been received by them or owing to any other reasons, the tenderer is unable to undertake the contract,
the empanelment will be cancelled and security deposit shall stand forfeited to BPPI. Such tenderer will
also be liable for all damages sustained by BPPI by reasons of breach of tender conditions. Such damages
shall be assessed by CEO, BPPI whose decision shall be final.
12. BLACK LISTING PROCEDURE
(a).Non performance of any tenderer or empanelment conditions will disqualify a laboratory to

participate in the next tender.
(b). To assess the correctness of the test results given by the empanelled Drug testing laboratory,
samples would also be taken and sent randomly to Govt. laboratory/ CPSUs Laboratories/ any other
NABL accredited labs which are not empanelled for testing and if any variation in the results is
found, the result would be informed to empanelled laboratory. If there is any major variation in the
analytical reports furnished by empanelled laboratories, (either pass or fail etc.) viz-a-viz Govt.
/CPSUs Laboratory/ any other NABL accredited labs, the empanelled laboratory will be blacklisted
for two years besides forfeiture of security deposit, after giving due opportunity to the concerned
laboratory.
(c). If it is revealed that Drug Testing Laboratory is involved in any form of fraud and collusion with
the suppliers of BPPI, the Drug Testing Laboratory will be black listed for five years. The

Page 10
tenderer shall also be liable for action under criminal law and matter will be informed to relevant
appropriate authorities for penal action against them.
(d). The CEO, BPPI will be at liberty to terminate the empanelment without assigning any reasons.
The tenderer will not be entitled for any compensation whatsoever in respect of such termination.
Note:
 
 In all matters pertaining to tender, the decision of CEO, BPPI shall be final and binding.

  arising out of tender, such dispute would be subject to the jurisdiction of civil
In event of any dispute
court within Delhi.

In case of dispute or difference arising between BPPI and empanelled Drug Testing
Laboratory relating to any matter arising out of or connected with this tender agreement, such
with the Arbitration and Conciliation Act
dispute or differences shall be settled in accordance
1996. The venue of arbitration shall be Gurgaon.
13. AGREEMENT FORMAT
(Contract for Empanelment of Drugs & Surgical Testing Laboratories for the Analysis
of DRUGS &Surgical )
7AGREEMENT MADE at _____________ this ________ day of_________________ 201 7at BPPI
Gurgaon between M/s _______ having its registered office at ________ (hereafter referred to as ‘The
Laboratory’ which term should include its successors, representatives, hires, executors, and
administrators unless excluded by contract) on FIRST PART and Bureau of Pharma Public Sector
Undertakings of India, set up under Department of Pharmaceuticals, Ministry of Chemicals &
Fertilizers, Government of India as a Society registered under the societies registration act XXI of
st
1860, having its Registered Office at Core No. 06, 1 Floor, SCOPE Complex, Lodhi Road, New
Delhi - 110003, through Mr. _________ S/o _____________ , ____________hereinafter referred to
as “BPPI” (which expression shall mean and include its successors and assigns) of the SECOND
PART.
WHEREAS the Laboratory has awarded a contract by BPPI to provide report and undertake the
analytical work of the BPPI, (the list of medicines mentioned in the Schedule attached hereto
Annexure-I and Annexure-II) at the rates noted therein and in the manner and under the terms and
conditions hereinafter mentioned.
And whereas the Laboratory has deposited a sum of Rs 20000/- (Rupees Twenty thousand only) as
Security Deposit for the due and faithful performance of this Agreement with the BPPI, which shall
be forfeited in the event of the Laboratory’s failure in performing its duties faithfully.
Now these presents witness that for carrying out the said Agreement in this behalf into execution,
The Laboratory and the BPPI do hereby mutually convenient, declare, contract and agree each of
them with the other of them in the manner following, that is to say,
Page 11
(1). The term “Agreement”, wherever used in this connection, shall mean and include the terms and
conditions in tender floated by the BPPI for Empanelment of Drugs Testing, laboratories for the
analysis of DRUGS & MEDICINES for the two years 2016-2018 the instructions to tenderer, the
conditions of tender, acceptance of tender particulars hereinafter defined and those general and
special conditions that may be added from time to time.
GENERAL TERMS & CONDITIONS:
(2). (a). The Agreement is for undertaking analysis of DRUGS & Surgical by the Laboratory to the
BPPI of the samples specified in the Schedule attached hereto Annexure-I and Annexure-II at the
rates noted against each therein on the terms and conditions set forth in the Agreement.
(b). This Agreement shall be deemed to have come into force with effect from _______________
and it shall remain in force for a period upto date of ______________ and may however be extended
for a further period, on mutually agreed terms.
(c) Laboratory shall perform services with care, skill, and diligence, in accordance with the
applicable professional standards currently recognized by such profession, and shall be responsible
for the professional quality, technical accuracy, completeness, coordination, and timeliness of all
items and services furnished under this Laboratory Agreement.
(d) Laboratory shall comply with all applicable NATIONAL, state, and local laws, ordinances,
codes, and regulations in performing services. If Laboratory fails to meet applicable professional
standards, Laboratory shall, without additional compensation, correct or revise any errors or
deficiencies in items or services furnished under this Agreement.
(e) Laboratory shall retain, at a minimum, accreditation to ISO/IEC as per rules granted by a national
accreditation body. Laboratory shall notify BPPI immediately if accreditation is in jeopardy or lost.
Upon BPPI’s request, Laboratory shall present BPPI with proof of its accreditation.
(f) For all requests made by BPPI pursuant to this Agreement, time is of the essence. The
acceptance of a late performance, with or without objections or reservations by BPPI, shall not waive
the right to claim damages for such breach nor constitute a waiver of the requirement of timely
performance of any obligations remaining to be performed.
(g) In accordance with the ASTM Standard, all required tests shall be conducted to completion.
INSPECTION OF LABORATORY:
(3) In respect of the analysis medicines in the Schedule, the drug testing Laboratory shall allow
inspection of the Laboratory at any time during the tender period by a team of Experts/Officials
whom the BPPI may depute for the purpose. The Laboratory shall extend all facilities to the team to
enable them to inspect premises, testing faculties, technical personals, reference standards/ working
standards/ documentation as mandatory under D & C Act 1940 and Rules 1945, in the Laboratory.

RECOVERY OF MONEY DUE TO BPPI FROM THE LABORATORY:
(4). All expenses, damages and other money payable to the BPPI by the drug testing Laboratory
under any provisions of this Agreement may be recovered from the amount due or subsequently
becoming due from the BPPI to the Laboratory under this or any other Agreement. In case such
amounts are insufficient to fully cover such expenses, damages or other money payable, it shall be
lawful for the BPPI to recover the balance amount from the security deposit of the Laboratory and all
other money held by BPPI and in case such Security Deposit is insufficient, then it shall also be
lawful for the BPPI to recover the residue of the said expenses, damages and moneys, if necessary,
by resorting to legal proceedings against the Laboratory.
AMOUNT OF SECURITY DEPOSIT TO BE MADE BY THE LABORATORY:
(5). The Laboratory shall deposit with the BPPI Rs. 20,000/- as security deposit by way of Demand
Draft favoring BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA payable
at Delhi/Gurgaon. This agreement comes into effect only after the laboratory has remitted the
required amount of security deposit, not withstanding anything contained in Para 2 (b) of this
agreement.
SUBMISSION OF BILLS FOR UNDERTAKING ANALYSIS:
(6). (a). No advance payment towards any analysis will be made to the Laboratory.
(b). All bills/invoices should be raised in duplicate in the name of BPPI. All payments shall be made
by way of cheque drawn in favour of Laboratory account and Crossed Account Payee / NEFT only.
The Laboratory shall furnish the details of their bank account no., name of bank and branch, IFSC
code no. etc to the BPPI. (An original cancelled cheque leaf issued by their bank should be
furnished).
ASSIGNMENT OF CONTRACT PROHIBITED:
(7). The Laboratory shall not, at any time, assign, sub-let or make over the present contract or the
benefits thereof or any part thereof, to any person or persons whomsoever.
TERMINATION OF CONTRACT ON BREACH OF CONDITION:
(8).(a). In case the Laboratory fails or neglects or refuses to faithfully perform any of the covenants
on his part herein contained or violates the condition in the tender document, it shall be lawful for
BPPI to forfeit the amount deposited by the laboratory as security deposit and cancel the contract
apart from black listing the laboratory for period of two years.
(b). In case of laboratory fails or refuses to observe, perform, fulfill and keep all or any other or more
or any part of anyone of covenants, stipulations and provisions herein contain, it shall be lawful for
BPPI on any such failure, neglect or refusal to put an end to this agreement and there upon every
article clause and thing herein contained on the part of BPPI shall cease and be void and in case of
any damage, loss, expense, differences in the cost or other moneys than or any time during the
continuance of this agreement becoming due or owing by the laboratory to BPPI, it will be opened

Page 13
for BPPI to recover from laboratory all such damages, losses, expenses, differences in cost or other
moneys as aforesaid it shall be lawful for BPPI to appropriate the security deposit made by laboratory
as herein before mentioned to reimburse all such damages, losses, expenses differences in cost and
other moneys as BPPI have sustained, incurred or put to by reason of the laboratory having seen
quality of any such failure, negligence or refusal as aforesaid or other breach in the performance of
contract.
(c). If at any time during the course of contract it is found that information given by the laboratory to
BPPI, either in tender or otherwise, is false, BPPI may put an end to contract / agreement wholly or
in part and thereupon the provisions of cause (a) shall apply.
(9). The BPPI reserves its right to terminate without assigning any reasons therefore the contract/
agreement either wholly or in part without any notice to the laboratory. The laboratory will not be
entitled for any compensation whatsoever in respect of such termination of contract by BPPI.
INDEMNIFICATION
(10) Laboratory will hold BPPI harmless and indemnify BPPI for any claim arising:
(1) from Laboratory’s noncompliance with applicable governmental laws or regulations,

(2) from injury to Laboratory personnel while performing Laboratory’s duties under this
Agreement, and
(3) in any manner from the services to be performed under this Agreement and caused by
Laboratory’s acts or negligence.
NOTICES ETC., IN WRITING:
(11). All certificates or notices or orders for the time or for extra , varied or altered laboratory, which
are to be the subject of extra or varied charges whether so described in the agreement or not, shall be
in writing and unless in writing shall not be valid, binding or be or any effect whatsoever.
LABORATORIES NOT TO HAVE ANY INTEREST IN THE OFFICERS CONCERNED

AND SUBORDINATED:
(12). The laboratory shall not be in any way interested in or concerned directly or indirectly with any
of the officers, subordinates or servants of BPPI in trade, business or transactions nor shall the
laboratory give or pay or promise to give or pay any such officer, subordinate or servant directly or
indirectly any money or fee or other consideration under designation of custom or otherwise nor shall
the laboratory permit any person or persons whomsoever to interfere in the management or
performance thereof under power of attorney or otherwise without obtaining the consent of BPPI in
writing.
BANKRUPTCY OF THE LABORATORY:
(13). In case the Laboratory at any time during the continuance of the Contract becomes bankrupt or
insolvent or commits any act of backrupcy or insolvency under the provisions of any law in that
behalf for the time being in force, or should compound with his creditors, it shall be lawful for the
BPPI to put an end to the Agreement, and thereupon every article, clause and thing herein contained

Page 14
to be operative on the part of the BPPI, shall cease and be void and the BPPI shall have all the rights
and remedies given to him under the precedent clauses.
SERVING OF NOTICES TO LABORATORY:
(14). All notices or communications relating to or arising out this agreement or any of the terms
thereof shall be considered duly served on or given to the laboratory if delivered to him or left at his
premises, place of business or above.
(15). And it is hereby agreed and declared between the parties hereto that in case any question of
dispute arises touching the construction or wording of any Para herein contained on the rights, duties,
liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision
of CEO, BPPI in the matter shall be final and binding on both parties.
(16) All disputes under this Agreement shall be resolved as follows. Within 15 days after written
notification of the dispute, principals or officers of Laboratory and BPPI shall meet in an effort to
resolve the dispute. If the dispute remains unresolved, the parties shall participate in a facilitated
mediation pursuant to the rules of the Indian Arbitration and Conciliation Act, 1996 , Such
disputes/differences shall be referred to Sole Arbitrator to be appointed by the President/ CEO of
BPPI in accordance with the provisions of Arbitration Act, 1996.
(17). In the event of any disputes between the parties the dispute would be subject to the jurisdiction
of civil courts within Delhi only.
(18) If any of the provisions of this agreement are held to be invalid or unenforceable in any respect,
the remaining terms will remain effective and the agreement will be construed as if the invalid or
unenforceable matters were never included in it. No waiver of any default will be a waiver of any
future default. Neither party shall be liable for nonperformance caused in whole or in part by Acts of
God, civil unrest and war.
In witness where the laboratory and CEO, BPPI acting for and on behalf of BPPI have set their hands
the day, month and year written above.
Authorized Signature of BPPI Authorized Signature of Laboratory
Name Name & designation

Address and Seal Address and Seal
Witnesses for BPPI Witnesses for Laboratory
Signature Signature
Name Name
Address Address
Page 15
ANNEXURE-I
Proforma for Performance Statement
(1). Name of Laboratory:
(2). Address:
(3). Performance Statement:
Sr. Category No. of samples (complete Total no. of

analysis) tested during
No. Samples
2015-16 2016-17
1 Tablets
2 Capsules
3 LVP / SVP
4 Dry Powder Injectables

(DPI)
4 Liquid Orals/Syrups/Susp.
6 Ointments/ Creams/ Gel/

Lotion
7 Eye/Ear Drops / Nasal Drops
8. Vaccines & Sera
9. No of samples failed
Note: Facilities for LAL test if available Yes/ NO

Page 16
ANNEXURE-II
Details of Laboratory and Certificate of Registration for Service Tax

(1). Name of Laboratory
(2). Address of Head Office, if any:
(3). Address of Laboratory
(4). Name of contact person
(5). Phone No. :
Mobile No.:
(6). E-mail :
(7). Details of Approval/ License issued by Drugs Regulatory Authority*
(8). Validity of Approval/ License issued by Drugs Regulatory Authority:
(9). NABL Certificate No. along with discipline*
(10). Validity of NABL Certificate:
(11). Certificate of Registration for Service Tax: To be enclosed
(12). Any other certificates with details*
* enclose duly attested copy

Page 17
ANNEXURE-III-A
Personnel in Laboratory
1) Total qualified technical personnel engaged in Chemical / Instrumental analysis:
2) Total qualified technical personnel engaged in Microbiological analysis:
3) Details of Competent (Approved) staff by State Licensing Authority
S. Name Designation Qualifications Approval in Chemical Experience

No. / Instrumental/ in relevant
Microbiological analysis
Testing (Years)
ANNEXURE-III-B
List of all functional Sophisticated Instruments/ Apparatus including used

for testing of Insulin, vaccines & sera etc.
S. Name of Total Number Make Date of
No. Instrument/ Installation
Apparatus
Enclose additional paper

Page 18
ANNEXURE-III-C
Facilities in Microbiological Section with AHU in Laboratory
1) List of reference cultures available: To be given

2) List of reference impurities available: To be Given
3) List of reference standard/ working references available: To be Given
4) Details of equipments (e.g. Incubators, Laminar Air Flow etc.)
S. Name of Total Make Date of

No. Instrument/ Number Installation
Apparatus
Enclose additional paper

Page 19
ANNEXURE-IV
Declaration Form (To be attested by Notary)
I / We _(Name of Bidder)_____________________________ having our Head Office at
____________________ and Drug Testing Laboratory at ____________________ do
hereby declare that I / we have carefully read all the conditions of the tender of Bureau of
Pharma Public Sector Undertakings of India (BPPI), Gurgaon for empanelment of Drugs
Testing Laboratories for analysis of DRUGS & MEDICINES for two year period (2017-
2019) and abide by all conditions said therein.
I/We further declare that we have valid approval/ license issued by Drug Regulatory
Authority bearing no. ____________ and NABL Certificate bearing no. _________ in
discipline ________.
Signature
Name of Authorized Person

Seal of Laboratory

Page 20
Annexure – VA
List of DRUGS for the Analysis of Medicines for THE YEAR

2017-2019
Sr. Drug quoted by as symbol ()

Generic name of Drug Unit Size
No. Code yes
Amoxicillin 250 mg; Lactic Acid Bacillus 60 MU

1 33 10's
Capsules
Amoxycillin 500mg + Bromhexine 8 mg
2 34 10's
Capsules
3 46 Ampicillin Injections I.P. 500mg Vial & WFI
4 51 Cefadroxil film coated Tablets IP 250mg 10's
5 67 ceftazadime 1000mg injection Vial with WFI
6 68 Ceftazadime 250mg Inj. Vial with WFI
7 69 Ceftazadime 500mg Inj. Vial with WFI
Ceftriaxone + Tazobactum 250 mg + 31.25 mg

8 72 Vial with WFI
Inj.
Co-trimoxazole (Sulphamethoxazole 200mg +

9 88 50ml bottle
Trimethoprim 40mg / 5ml) Susp
Co-trimoxazole-Pead. Tab.
10 90 (Sulphamethoxazole 100mg+Trimethoprim 10's
20mg) Tablets
Erythromycin Stearate 250mg film coated
11 93 10's
Tablets
12 99 Norfloxacin 400mg film coated Tablets 10's
13 107 Tinidazole 300mg film coated tablet. 10’s
Beclomethasone 0.025%+ Neomycin 0.5%
14 113 15g tube
w/wCream
Beclomethasone Dipropionate 0.025% w/v
15 114 15g tube
Oint.
16 116 Chlorhexidine Gluconate 5% Solution 500ml bottles
17 118 Clobetasol Propionate 0.05 % w/w Cream 15g tube
18 122 Ketoconazole 2% w/w Lotion 100ml Bottle
19 123 Lignocaine 2% w/w Ointment 30 g tubes
Chlorhexidine 1.5%w/v +Cetramide 3%w/v

20 130 100ml Bottle
Solution
21 146 Pioglitazone 15mg tablet 10's
22 148 Pioglitazone 15mg + Glimeperide 1mg Tablets 10's
23 149 Pioglitazone 15mg+ Glimeperide 2mg Tablets 10's
24 151 Dihydroergotamine 1mg film coated Tablets 10's
25 157 Etoposide 100mg Caps 10's
Medroxyprogestrone Acetate 10 mg film
26 161 10's
coated Tablets
27 162 Raloxifene 60 mg Tab 10's
500 ml
28 166 Dextrose 10% (10D) Injections
bottles
500 ml
29 167 Dextrose 5% (5 D) Injections
bottles
500 ml
30 168 Glucose Normal Saline (DNS) solutions
bottles
31 171 Mannitol 20% Infusion IP 350ml
32 173 Normal Saline (NS) solutions 500ml
Dicyclomine 20mg+ Mefenamic Acid 250 mg
33 182 10's
Tabs
Dicyclomine Hcl20mg+Paraceatmol325mg
34 184 10's
tablet
Diethylcarbamazine citrate 100mg film coated
35 185 10's
Tablets
Norfloxacin 100mg+ Metronidazole 100mg/5
36 204 30ml bottle
ml Syrup
Ofloxacin 50mg+ Metronidazole 100mg/5ml
37 205 30ml bottle
Syrup
Iron (Carbonil Iron) 100mg + Folic Acid 1.5mg +
38 226 15's
Zinc Capsules
Iron Tonic Carbonil Iron 100mg + Folic Acid 200 ml
39 228
1.5mg + Zinc each 5ml Syrup bottles
40 236 Budesonide 100mcg Rotacaps 30 Rotacaps
41 237 Budesonide 200mcg Rotacaps 30 Rotacaps
42 238 Budesonide 200mcg/dose Inhaler 200md

Levocetrizine HCl 5mg +Pseudoephedrine
43 249 10's
20mg+ Paracetamol 325mg Tablets
44 255 Salbutamol 100 mcg/puff Inhaler 200 md
45 257 Salbutamol 2.5mg Respule 2.5ml
46 258 Salbutamol 200mcg Rotacaps 30's
47 261 Adenosine 6 mg/ 2ml Amp. 2ml
48 262 Amiodarone 100 mg Tabs 10's
49 268 Clonidine 0.1 mg Tabs 10's
50 272 Diltiazem 60mg Tablets 10's
51 284 Isosorbide Mononitrate 10mg Tabs 10's
52 292 Nifedipine 10mg Capsules 10's
53 297 Tamsulosin Hydrochloride 0.4 mg Capsules 10's
54 303 Artesunate 50mg Tabs 10's
Chloroquine Phosphate 250 mg film coated
55 305 10's
Tablets
56 307 Primaquine 2.5 mg film coated Tablets 10's
57 308 Primaquine 15 mg film coated Tablets 10's
Sulphadoxine 250mg+Pyrimethamine
58 309 10ml bottles
12.5mg/5ml Syrup
Sulphadoxine 500 mg +Pyrimethamine 25mg
59 310 10's
Tablets
60 315 Betahistine 16mg Tablets 10's
61 332 Thyroxine Sodium 100 mcg Tablet 100's
62 339 Betaxolol Hydrochloride 0.5 % w/w Eye Drop 5ml
63 340 Acyclovir 3% w/w Eye Onitment 5 gm
64 342 Chloramphenicol 0.5 % w/v Eye Drop 5ml
65 343 Chloramphenicol 1%w/v Eye Applicaps 100 Applicaps
66 346 Ketorolac Tromethamine 0.5 % w/v Eye Drop 5ml

67 347 Prednisolone Acetate 1 % w/v Eye Drop 5ml
68 350 Timolol Maleate 0.5 % w/v Eye Drop 5ml
69 353 Ketamine Hydrochloride 10mg/ml Inj. 10ml
70 354 Ketamine Hydrochloride 50mg/ml Inj. 2ml
71 355 Lignocaine 1% w/v Inj. 20ml Vial

BIPHASIC ISOPHANE INSULIN INJECTION IP 4O
72 362 10 ml Vial
IU/ML (50:50 )
Cartridge/Vial
73 363 Insulin Glargine 100 IU Injections
3ml
Glimepiride2mg+MetforminHydrochloride
74 364 15's
500mg SR tablet
75 365 Gliclazide80mg+MetforminHcl tablet500mg 15,s
76 367 Voglibose tablet 0.3mg 10,s
77 368 GLICLAZIDE TABS/CAPS SR 60MG 10's
78 369 Acarbose tablet IP 50mg 10,s
Metformin Hydrochloride Tablets IP Prolong
79 372 10's
Release 500 MG
80 377 Clindamycine capsule IP 300mg 10,s
EACH KIT CONTAIN RIFAMPICIN TABLET IP
450MG, ISONIAZIDE TABLET IP 300MG
81 378 1's
ETHAMBUTOL TABLET IP 800MG AND
PYRAZINAMIDE TABLETS IP 750MG
Rifampicin and Isoniazide Tablets IP (450
82 379 10's
MG+300 MG)
83 387 Tebinafine tablet250mg 7,s
EACH KIT CONTAIN RIFAMPICIN TABLET IP
84 388 450MG, ISONIAZIDE TABLET IP 300MG and 1's
ETHAMBUTOL TABLET IP 800MG
85 389 Penicillin G Pottasium Tablets 400000 U 6's
86 392 GRISEOFULVIN TABLETS IP 250 MG IP 10's
87 393 ACYCLOVIR 800MG DISPERSIBLE TABLETS IP 5's
PYRANTEL PAMOATE ORAL SUSPENSION IP 250
88 394 10ml
MG/10 ML IP
89 397 Oxytetracycline Cap I.P 250 MG 10's
RIFAMPICIN 100MG, ISONIAZIDE 50MG and
90 399 10's
PYRAZINAMIDE 300MG TABLETS IP
91 412 AZATHIOPRINE TABLETS IP 50 MG 10's
92 413 METHOTREXATE TABLETS IP 7.5 MG 10's
93 415 GLYCERYL TRINITRATE TABLETS IP 2.6 mg 25's
94 416 Prazosin Tablets IP 5 mg 15's
TELMISARTAN 40 mg + AMLODIPINE 5 mg
95 417 15's
TABLETS
HEPARIN SODIUM 50 IU, Benzyl Nicotinate
96 419 20gm
2mg/gm Cream
ATORVASTATIN 10 MG+ CLOPIDOGREL 75 MG
97 420 10's
CAPSULES
98 421 NEBIVOLOL TABLETS IP 5 MG 10's
99 422 Torsemide Tablets 10 MG 15's
100 423 Bisoprolol Tablets 5 MG 10's
101 424 Carvedilol Tablets IP 3.125 MG 10's
102 425 DILTIAZEM TABLETS SR 90 MG 10's
103 427 S-AMLODIPINE TABLETS IP 2.5 MG 10's
104 430 AMIODARONE Tablets IP 200 mg 10's
RAMIPRIL and HYDROCLORTHIAZIDE TABLETS
105 431 10's
IP (5MG+12.5 MG)
106 437 Nifedipine Prolonged Release Tablets IP 20MG 10's
107 438 INDAPAMIDE TABLETS IP 1.5 MG 10's

OLMESARTAN MEDOXOMIL 40mg +
108 439 10's
HYDROCLORTHIAZIDE 12.5mg Tablets
109 440 Metoprolol 50 MG + Amlodipine 5 MG Tablets 7's
110 441 Losartan 50mg+Amlodipine 5mg tablet 10,s
111 443 ISOSORBIDE DINITRATE TABLETS IP 5 MG 50's
Enalapril 10 MG + Hydroclorthiazide 25 MG
112 444 30's
Tablets
OLMESARTAN 20mg+ AMLODIPINE 5mg
113 445 10's
Tablets
114 450 Labetalol tablet IP 100mg 10,s
115 452 Warfarin tablet IP 5 mg 10,s
116 455 Verapamil tablet IP 80 mg 10's
117 456 Atorvastatin tablet IP 40mg 10,s
DICYCLOMINE 10 mg+ MEFENAMIC ACID 250
118 467 10's
mg Tablets
Domperidone 30mg+ Esomeprazole 40mg
119 472 10,s
tablet
LEVOSULPIRIDE 75 MG+ PANTOPRAZOLE 40
120 473 10's
MG CAPSULE
TRICHOLINE CITRATE 550MG + SORBITOL
121 479 200 ML
7.15GM SYRUP/10ML
122 483 LOPERAMIDE Capsules IP 2mg 10's
123 488 LANSOPRAZOLE CAPSULES IP 15MG 10's
124 491 ITOPRIDE Tablets 50mg 10's
125 492 Sulfasalazine Tablets EC BP 500 MG 10's
126 493 Ispaghula Husk IP 50GM 50 GM
127 494 Ispaghula Husk IP 100GM 100gm
FERROUS ASCORBATE 100MG WITH FOLIC
128 498 10's
ACID 1.5MG TABLETS
100's in A
129 500 LEVO-THYROXINE TABLETS IP 100MCG
Bottle
NANDROLONE DECANOATE INJECTION IP

130 504 1ml
25MG/ML
100's in
131 505 CARBIMAZOLE TABLETS IP 10mg
Bottle
132 507 CARBIMAZOLE TABLETS IP 5 MG 10's
133 516 ACECLOFENAC Tablets SR/CR 200 mg 10's
THIOCOLCHICOSIDE 4 mg+ ACECLOFENAC 100
134 517 10's
mg Tablets
135 518 BACLOFEN Tablets IP 10 mg 10's
136 519 Ketorolac tablet DT 10 mg 10's
137 521 TRAMADOL TABLETS SR 100 MG 10's
138 524 LIDOCAINE INJECTION IP 2 %W/V 30 ML VIAL
GUAIFENESIN 100mg+ TERBUTALINE 2.5mg+

139 531 100ml Bottle
BROMHEXINE 8mg/10ml SYRUP
Fluticasone 250MCG, Salmeterol

140 532 30 Rotocaps
50mcg/Rotacap
Beclomethasone Dipropionate 200 MCG,

141 534 30 Respicap
Salbutamol 400 MCG Rotacap
142 539 ACETYLCYSTEINE Tablets 600mg 10's

LEVBUTEROL 1.25 MG+ BUDESONIDE 1MG
143 540 2ml
REPSULE
MONTELUKAST 10MG + FEXOFENADINE HCl
144 556 10's
120MG TABLETS
FLUTICASONE PROPIONATE 50 MCG PER PUFF
145 560 120 MDI
NASAL SPRAY
146 566 IPRATROPIUM 250 MCG/ML SOLUTION 15ml
SALBUTAMOL 100 MCG + IPRATROPIUM 20
147 567 100 MD
MCG /PUFF INHALER
Salmeterol 50 Mcg, Fluticasone Propionate 250
148 568 120 MDI
Mcg/1 Dose Inhaler
TAMSULOSIN 0.4 MG + DUTASTERIDE 0.5 MG
149 571 15's
TABLETS
150 581
151 588 VITAMIN E SOFTGEL CAPSULES 400 MG 10's
Calcium Citrate Maleate 500MG & Calcitriol
152 589 15's
0.25mcg Capsules
153 591 METHYLCOBALAMIN 500MCG INJECTION 1ml
154 594 Glucose Powder 75gm
155 596 ZINC SULPHATE 20 MG/ ML ORAL SOLUTION 15ml
PREGABALIN 75 mg+ METHYLCOBALAMIN
156 598 10's
750mcg Tablet SR
157 599 PREGABALIN TABLETS 75MG 10's
Beclamethasone Dipropionate..0.025% w/,
158 607 Neomycin 0.5% w/w ( 3500 Unit /G) 15 GM
Chlorocresol 0.1% w/w cream
Silver Nitrate0.20%w/w,Chlorhexidine
159 609 gluconate solution 0.20%,presrvative 15gm tube
chlorcresol0.12%w/w
Cyproheptadine Hydrochloride(anhydrous) IP.
160 611 200ml
2 mg in a flavoured syrup
161 616 Celecoxib 100mg capsules 10's
162 617 Celecoxib 200mg capsules 10's
Cough lozenges Ginger / Lemon (2,4

163 622 Diclorobenzyl alcohol1.2 mg + Amylmetacresol 1's
0.6 mg in Ginger /Lemon flavour
Cough lozenges Regular 2,4 - Diclorobenzyl

164 623 1's
Alcohol 1.2 mg, Amylmetacresol BP 0.6 mg
Etophylline IP 231mg. + Theophylline 69mg
165 628 10's
Tablet
Inhalent Softgel Caps. (Camphor 25 mg +
166 629 Clorothymol 5 mg + Eucalyptol 130 mg + 10's
Menthol 55 mg + Terpineol 110 mg)
167 631 Ethamsylate B.P 500 mg 10's
168 632 Ethamsylate B.P 250 mg 10's
clobetasol Propionate 0.05 % w/w Neomycine
169 634 sulphate 0.50%, miconazole nitrate 2.0%w/w, 20gm tube
Chlorcresol0.10% IP Cream
Enyme Syrup Cardamom Flavour Pepsin 7.5 mg
170 654 200ml
+ Fungal Diastase 12.5 mg / 5 ml
Gama Benzene Hexachloride 1 % w/v +
171 661 100ml Bottle
Cetrimide 0.1% w/v lotion
Gama Benzene Hexachloride 1 % w/v +
172 662 200ml
Cetrimide 0.1% w/v lotion
B Complex with vitamin C Each capsule
contains - Thiamine mononitrate IP-
10mg,Riboflavin IP -10 mg,Pyridoxine HCl IP-
173 665 10's
3mg,Vitamin B 12 IP - 5mcg,Niacimnamide IP -
50mg,Calcium Pantothenate IP-12.5mg,Flolic
Acid IP -1mg, Ascorbic Acid IP- 150mg
Multivitamin Drops : Vitamin A(as Palmitate)IP

2500 IU, Vitamin E Acetate IP 2.5 IU,Vitamin
D3 IP 200 IU,Ascorbic Acid IP 40mgThiamine
174 668 15ml
Hydrochloride IP 1mg,Riboflavine Sodium
Phosphate IP 1.5mg,Niacinamide IP 10mg,D-
Panthenol IP 3mg,D-Botin BP 50mcg ,Lysine
175 673 Biotin 10mg Tablet 10's
176 677 Flupentixol 0.5 mg Tablet IP 10's
Levodopa & Carbidopa tab (250 mg + 25 mg)
177 678 10's
Tab. IP
178 679 Nalidixic Acid 500 mg Tablet IP 10's
179 681 Phenazopyridine Hcl 100mg tab 10's
Pantoprazole 40mg + Domperidone 30mg S.R.
180 684 10's
Capsules
181 687 Lactulose10 gm/15ml 200ml
182 693 Tropicamide 1% Eye Drops IP 5ml
Polymyxin B sulphate BP 5000 iu ,
183 695 Chloramphenicol IP 4mg Phenylmercuric 5ml
nitrate 0.001% Eye drops IP
Polymyxin B sulphate BP 5000 iu ,
Chloramphenicol IP 4mg ,Dexamethasone
184 696 5ml
sodium phosphate IP 1 mg Phenylmercuric
nitrate 0.001% Eye drops IP
185 700 Ketamine Hydrochloride Injection IP 50 mg/ml 20ml Vial
186 701 Pilocarpine Eye drop IP 2 % 10 ml Vial
187 702 Haloperidol Tablet IP 0.5 mg 10's
188 705 Levofloxacin Infusion IP 500mg 100ml Bottle
189 707 Piroxicam Capsules IP 10 MG 10's

190 708 Piroxicam 20 mg tablets 10's
191 714 Ofloxacin 200mg+Ornidazole 500mg infusion 100 ML
192 717 Etodolac tablets 300mg IP 10's
193 721 Sterile Water for Injection I.P. Amp Polypack 2ml
194 722 Sterile Water for Injection I.P. Amp Polypack 5ml
Dextrose Injection IP 5 %, i.v fluid plastic
195 725 500ml
container using FFS technology
Dextrose Injection IP 10 %, i.v fluid plastic
196 726 500ml
Sodium Chloride (0.9% W/V) and Dextrose 5%
197 728 w/v Injection IP,i.v fluid plastic container using 500ml
FFS technology
Sodium Chloride Injection IP 0.9%w/v(Normal
198 732 Saline ( NS ) 0.9% w/v),i.v fluid plastic 100ml
199 755 Povidone Iodine Medicated paint 10 % 50ml bottle
200 767 Metformin 1000mg SR +Glimepiride 2mg tablet 10,s

201 793 Atenolol tablet 25 mg 14,s
202 840 Citicoline tablet 500 mg 10''s
203 863 Dextrose injection IP 25% 100ml
204 889 Febuxostat tablet iP 80mg 10's
205 904 Glimepiride 1mg +Metformin SR 500 mg tablet 10's
206 968 Mitrazapine tablet 15mg 10's
Nebivolol 5 mg, Hydrochlorothiazide 12.5 mg
207 975 10's
Tab.
208 976 Nebivolol Tablets IP 2.5mg 10's
209 978 Nepafenac 0.1% w/v Eye Drop 5ml
210 980 Nicorandil PR Tablets I.P 10mg 10's
211 974 Natural Micronised progestrone Capsules 10's
212 1012 Piracetam tablet400mg 10's
213 1026 Propanolol tablet IP 10mg 10's
Salmetrol 50mcg +Fluticasone Propionate
214 1046 120mdi
250mcg/1 doseMultihaler Mdi
215 1050 Sertraline tablet IP 100mg 10's
216 1074 Telmisartan 80mg +Hydrchlothiazide 12.5 mg 10's
217 1098 Voglibose 0.2mg+Metformin 500 tablet 10's
218 1106 Telmisartan 40mg +Metoprolol 50mg Tablets 10's
219 1107 Pregabalin Capsules 75mg 14's
220 1108 Sildenafil Tablets 100 mg 4's
221 1109 Prazosin Tablets 2.5mg 30's
222 1110 Clobazam Tablets 5mg 10's
Gabapentin 400mg + Nortriptyline 10mg
223 1111 10's
Tablets
224 1112 Cinnarizine Tablets 25mg 10's
225 1113 Pioglitazone Tablet IP Strength 7.5 mg 10's
Moxifloxacin Hydrochloride Sterile Ophthalmic
226 1114 5ml
solution 0.5% w/v
Gatifloxacin Hydrochloride Sterile Ophthalmic
227 1115 5ml
solution 0.3% w/v
Ciprofloxacin Hydrochloride Sterile Ophthalmic
228 1116 3gm
ointment 0.3%
Loteprednol Etabonate Sterile Ophthalmic
229 1117 5ml
suspension 0.5% w/v
230 1118 Moxifloxacin Sterile eye ointment 0.5% w/w 5gm
Moxifloxacin 0.5% w/v and Dexamethasone
231 1119 5ml
0.1%w/v Sterile Eye drops
Gatifloxacin 0.5% w/v and Dexamethasone
232 1120 5ml
Ciprofloxacin 0.3 % w/v and Dexamethasone
233 1121 5ml
Chloramphenicol 1 % w/v and Dexamethasone
234 1122 5ml
235 1123 Clomipramine Hydrochloride SR Tablets 75mg 10's
236 1124 Fluvoxamine Hydrochloride Tablets 100mg 10's
237 1125 Aripiprazole Tablets 5mg 10's
Mecobalamin 1500mcg, Alpha lipoic acid
238 1126 100mg, Benfotiamine 100mg, Vitamin B6 3mg, 10's
Folic acid 1.5mg Capsules
239 1127 Human Albumin Solution 20% 50 ml
240 1128 Fenofibrate Tablets 145 mg 10's
TENELIGLIPTIN 20MG + METFORMIN 500 MG
241 1129 10's
Tablet
TENELIGLIPTIN 20mg + METFORMIN 1000mg
242 1130 10's
Tablet
Annexure- VB- List of Surgical items
List of Surgical items

quoted
by as
1 2 symbol
3 4 () yes
Sr. Item Code Unit Size
Name and description of
No.
Items
1 5001/5002/5003 Absorbent Cotton Wool I.P. 75 1's
/200/500 gm (Non Sterile)
2 5004/5005 Crape Bandage B.P. 15 cmX4 12
meter/10cmx4meter
3 5006/5007/5008 Cotton Bandages(Non Sterile) , Size 1X12
7.5 /10cm/15cmcmX4M as per
Schedule F-II
4 5009 Adhesive Bandages Washproof 19 1's
mmx72 mm or 19mm X 70 mm
containing Benzalkonium Choride
Solution IP eq. to Benzalkonium
Chloride 0.5%W/W
5 5010/5011/5012/5013/5014/5015/5016/5017/5018 Sterile Hypodermic Syringe with 1's
Needle attached, , Single use-
different sizes, IS 12050 (Sterile,
single use, disposable, as per BIS/CE
Certified)]
6 5073 Crepe Bandage B.P. 6 cmX4 meter 12
7 5074/5075/5076 A.V.Fistula Needle (Pair)15/16/17G 1's
8 5077 Malaria antigen pan/tester P.f. 1's
Test Kit
9 5078 Dengue Antigen (NS1) Test Kit 1's
10 5079 HCG -Pregnancy Card Test Kit 1's
11
12 5080/5081/5082 Sterile Disposable Spinal Needle for 1's
Single Use 23/26/27G x 3 ½ inch
13 5083 Ear buds 100% COTTON ,IDEAL 60 swab
SIZEFOR CLEANING
14 5084/5085/5086/5087/5088/5089/5090 Surgical Blade, Sterile ,different Size 1's
Single peel pack in metal foil ,be
smooth and free from tool marks and
any sign of corrosion.
15 5091/5092/5093 Micropore Surgical PAPER TAPE ALL 6rolls/box
SIZE
18 5094/5095/5096 sterile gauze pad size 2"X2"/3x3/4x4 10's
19 5097 Alcohol Swab (Spirit Swab) 1's

20 6050/6051/6052 Knee Cap Small/medium /large pair
21 6053 Disposable Sterile Surgical Rubber Pair
Gloves, Size 6 ½ Inches, Conforms to
IS 13422,ISI marked / CE certified /
FDA approved
22 7001 Hot water Bag SIZE 1's
25.5cmx17.8cm(10”x7”)BS:1970:2012
23 7002 Clinical Thermometer As per IS 3055 1's

(Part-1) Specification/CE certified,
GLASS
24 8085/8086 Oxygen Mask, Size: Paed/adult 1's
25 8087 Automatic Snap-Out Folding Walking 1's
Cane Stick with Adjustable Length -
Color: Copper Easy & Quick to Use
Walking Cane for Treks, Casual Walks
or Outdoor Travel.
26 Release The Stick and 4 Folding
Sections Snap Out Automatically to
Make a Rigid Cane.
27 Lightweight Anodized Aluminum
Pole. Contour Grip Handle with
Rubber Bottom.
28 Sections Folds Conveniently In Its
Own Wallet. Adjustable Length: 33
inch to 37 inch.
29 Package Contains 1Pc Adjustable
Metal Walking Cane.
30 8088 Walking Stick with three supporter- 1's
light weight length 33 inch to 37 inch
31 8089/8090/8091/8092/8093/8094 Abdominal Belt Velcro after surgery 1's
or after delivery to support
abdominal region Cream color - Large
/medium/small
32 8095/8096/8097/8098 Anklet Binder Valcro pair Soft 1's
patella, Dual grip, Four way
stretchable fabric, Controlled
compression, Convenient application
Size Small/medium/large
33 8099/8100/8101/8102 Cervical Collar -designed to meet the 1's

needs of ambulatory patients over
and extended time. Technologically
advanced Sorbatex padding adds long
term comfort by quickly absorbing
moisture away from the skin.
Anatomical
shape,Wellventilated,High density PU
foam,Skin matching shades,Hypo-
allergenic covering
Small/medium/large
34 8103/8104/8105/8106 Thumb and Wrist brace - Soft 1's

Neoprene thumb cover • Pre-shaped
and removable metal stays for wrist
and thumb • Distal brace edge
situated under the palmar crease •
Brace is contoured at the ulnar
aspect of the hand • Elastic material
• High coverage of dorsal aspect of
the hand • Reliable thumb support •
Convenient application Small
/medium/large
36 8107/8108/8109 Knee Brace Belt - Excellent Support 1's
and Targeted Pain Relief • May
Relieve the Pain Associated with Mild
Osteoarthritis (OA) of the Knee •
Unilateral Hinge and Strapping
Configuration Apply Corrective Force
to Offload the Affected Side of the
Joint • Wrap-Around, Patient-
Friendly Design - Easy to Apply to
Swollen Tender Knees • Neoprene
Provides Therapeutic Warmth to
Soothe the Aching Joint • Support
Straps Allow for Adjustable
Compression • Available in Medial
and Lateral Designs for Left and Right
Knee Applications • Interchangeable
Condyle Pads for Day-to-Day
Adjustment Size-
small/medium/Large
37 8110/8111/8112 UROMETER - Three Chamber system 1's
Measuring glass capacity : 400ml
38 Urine collection bag for convenient
drainage of urine.,Inlet tube 120cm-
170cm
39 Sampling Port (needleless), Bed-
Sheet Clamp,Drainage control knob
effectively drains urine.,Hanger&
string for convenient and firm fixing
of the urine meter to the upper side
frame of the bed, Anti-reflux drip
chamber.,Exact and fine scaling for
timed measurements,Urine sampling
points at connector and measuring
glass,Germs and liquid tight,
hydrophobic coated filter for
pressure equalisation
40 Long, highly flexible and bend-

protected tube,Single hand, easily
operated outlet valve,Sterile by ETO
41 Urine collection bag for convenient
drainage of urine.,Inlet tube 120cm-
170cm
42 Sampling Port,Bed-Sheet
Clamp,Drainage control knob
effectively drains urine.
43 Hanger & string for convenient and
firm fixing of the urine meter to the
upper side frame of the bed.,Anti-
reflux drip chamber.,Exact and fine
scaling for timed
measurements,Urine sampling points
at connector and measuring glass
44 Germs and liquid tight, hydrophobic

coated filter for pressure equalisation
45 Long, highly flexible and bend-

protected tube,Single hand, easily
operated outlet
valve,LatexFree,Sterile by ETO
46 8113 Hernia Belt - made from good 1's
quality surgical Elastic with
elasticated straps, pads can be
adjusted. Size Universal (SIZE :
Small/Medium/Large)
47 8114 E.C.G ElectodesLiquid gel system, 1's
Long time duration,Foam/
Aggressive, Dimension (HxWxT)
50X48X1 mm
48 8115 Vacuum Extractor Set, manual 1's
operated.Complete with 3 stainless
steel cups (40, 50, 60mm).
Autoclavable Silicone pressure tube,
Traction handle.Suction pump, glass
jar fitted between M.S. Basket with
vacuum gauge and control valve.
49 8116 IV Cannula Fixer Good aesthetic 1's
appeal due to woven fast edges,
Moisture responsive High Moisture
vapour Transmission rate Film, Low
allergy grid pattern adhesive, Porous
adhesive to allow skin breathing, Easy
and Painless remove, because of thin-
non adhesive edges and leaves no
residue after remove.Medium : 6cm x
5cm
50 8117 Cervical Pillow- Designed to decrease 1's

morning pain and stiffness , Height
12.3 Centimeters, Length 20.3
Centimeters, Width 3.08 Meters,
Weight 680 Grams, Material
Polyester, Shell Soft
51 8118/8119/8120 Sample Blood Collection Needles 12 set
With Hub with optical venipuncture
control can make an important
contribution to simplifying blood
collection routine for phlebotomists.
The needle has a transparent plastic
hub, which functions as a view
window. If venipuncture is successful,
the view window is coloured red due
to the blood flow.different sizes.
Annexure – VI
Ref. Clause no. 2 (e), 5. vi
Declaration
I …………………………Managing Director/Partner/Proprietor of M/s
…………………………………………………………….. having its registered
office at ……………………………………………… ………………………
do hereby declared that our company have not banned/black listed/ debarred /
deregistered/ either by any state Government or central Government
Organization or its drug procurement agencies. We are eligible to participate in
tender no…………
M/s ………………….
Company Seal
To be attested by Notary

Page 40
Annexure – VII
CHECK LIST
S. No. Particulars Page No. Yes No

1. Annexure VI - Checklist
2 EMD in the form of DD shall be kept in an envelope.
3 Self attested and notorised Photo copy of licence for Drug
Testing Laboratory renewed upto ate.
4 Recognition Certificate issued by NABL & its renewal
5 Annual Turn over for the last two years certified by the auditors.
i.e. 2014-2015 & 2016-2017 certified by the auditors.
6 GLP compliant under the provisions of Drugs & Cosmetics Act
1940 and Rules 1945 (Schedule L1 certificate.
7 Certificate for analysis issued by other recognized agencies
8 Non conviction certificate as per pera 3(e)
9 Annexure – I Proforma for performance statement
10 Annexure – II Details of Laboratory and Certificate of
Registration for service tax
11 Annexure – III (A) Personnel in Laboratory.
12 Annexure – III (B) List of Sophisticated instruments.
13 Annexure – III (C) Facilities in Microbiological section
14 1) List of reference cultures available:
15 2) List of reference impurities available:
16 3) List of reference standard/ working references available
17 Annexure – IV Declaration form duly signed & notarized.
18 Annexure – VA List of DRUGS
Annexure – VB List of Surgical
19 Annexure – VI Declaration as pera 2(e
20 Documentary evidence, for the constitution of the company /
laboratory ie., Memorandum and articles of
Association or partnership etc.,
21 The instruments such as power of attorney, resolution of board
etc.,
22 The tender document signed by the tenderer in all pages with
official seal
23 Documentary evidence of having analyzed drugs for the test for
the last two years
24 Whether lab engaged in mfg activities (If yes, give details)
25 Cover B: Annexure – VII (Price Bid) Hard and softcopy in a
separate cover
Page 42
Annexure – VIIIA
Price Bid For Drugs
S. No. Drug Name of Medicine Unit Size Rate Tax Total Remarks
Code excluding applicable including
Tax(Rs) in % Taxes(Rs)
1
2
3
4
5
6
7
Enclose Soft Copy of Price Bid (in Excel Sheet) in CD also.
Annexure – VIIIB
Price Bid For Surgical
S. No. Drug Name of Medicine Unit Size Rate Tax Total Remarks
Code excluding applicable including
Tax(Rs) in % Taxes(Rs)
1
2
3
4
5
6
7
Enclose Soft Copy of Price Bid (in Excel Sheet) in CD also

Page 43

BPPI RC For Surgical Items

Загружено:

Сведения о документе

Оригинальное название

Авторское право

Доступные форматы

Поделиться этим документом

Поделиться или встроить документ

Параметры публикации

Этот документ был вам полезен?

Это неприемлемый материал?

Авторское право:

Доступные форматы

BPPI RC For Surgical Items

Загружено:

Авторское право:

Доступные форматы

NOT TRANFERABLE

TENDER NO. :- BPPI/Drugs&SurgicalTesting/048-2017

TENDER FOR EMPANELMENT OF DRUGS TESTING

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

BPPI/Drug & Surgical Testing/048

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR

Phone: 0124-4040768 Phone: 0124-45567554

BPPI/Drug & Surgical Testing/048

Sl. No. Description Page No.

BPPI/Drug & Surgical Testing/048

TENDER FOR EMPANELMENT OF DRUGS & SURGICAL TESTING

“CONFIDENTIALITY IS THE ESSENCE OF THIS TENDER”

NOTE:- LATE TENDER IS NOT ACCEPTABLE

BPPI/Drug & Surgical Testing/048

BPPI/Drug & Surgical Testing/048

(ii). List of sophisticated instruments (working condition) available in Drug Testing

(iii). Facilities available in Microbiological Section in the laboratory

[h]. Details of DRUGS & Surgical to be analyzed to be given in Annexure-VA & VB

OTHER DOCUMENTS TO BE ENCLOSED: [self attested and notarized]

4. PRICE BID (COVER-‘B’)

BPPI/Drug & Surgical Testing/048

iii. The rates should be exclusive of taxes.

v. If in any circumstances (like breakdown of instrument or non-availability of reference

BPPI/Drug & Surgical Testing/048

9. COMPLETE ANALYSIS AND REPORTING CONDITION

BPPI/Drug & Surgical Testing/048

(f). Spectra/Chromatograph/Dissolution profile, or other data sheets, wherever applicable, should be

(j). If in any circumstances (like breakdown of instrument or non-availability of reference standard

10. PAYMENT PROVISIONS

i. No advance payment towards any analysis will be made to tenderer.

11. PENALTIES PROVISIONS

12. BLACK LISTING PROCEDURE

(a).Non performance of any tenderer or empanelment conditions will disqualify a laboratory to

BPPI/Drug & Surgical Testing/048

13. AGREEMENT FORMAT

GENERAL TERMS & CONDITIONS:

BPPI/Drug & Surgical Testing/048

AMOUNT OF SECURITY DEPOSIT TO BE MADE BY THE LABORATORY:

SUBMISSION OF BILLS FOR UNDERTAKING ANALYSIS:

ASSIGNMENT OF CONTRACT PROHIBITED:

TERMINATION OF CONTRACT ON BREACH OF CONDITION:

BPPI/Drug & Surgical Testing/048

(1) from Laboratory’s noncompliance with applicable governmental laws or regulations,

LABORATORIES NOT TO HAVE ANY INTEREST IN THE OFFICERS CONCERNED

BANKRUPTCY OF THE LABORATORY:

BPPI/Drug & Surgical Testing/048

SERVING OF NOTICES TO LABORATORY:

Authorized Signature of BPPI Authorized Signature of Laboratory

Name Name & designation

Witnesses for BPPI Witnesses for Laboratory

BPPI/Drug & Surgical Testing/048

(3). Performance Statement:

Sr. Category No. of samples (complete Total no. of

4 Dry Powder Injectables

6 Ointments/ Creams/ Gel/

7 Eye/Ear Drops / Nasal Drops

8. Vaccines & Sera

Note: Facilities for LAL test if available Yes/ NO

BPPI/Drug & Surgical Testing/048

Details of Laboratory and Certificate of Registration for Service Tax

(2). Address of Head Office, if any:

(3). Address of Laboratory

(4). Name of contact person

and Drug Testing Laboratory at do